Cargando…
666. Outcomes Using Cefiderocol for the Treatment of Acinetobacter baumannii Infections from the PROVE (Real-World Evidence) Study
BACKGROUND: PROVE is an ongoing international, retrospective study assessing cefiderocol (CFDC) for Gram-negative (GN) infections. Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are difficult-to-treat with limited treatment options. CFDC is a novel sidero cephalosporin with activity...
Autores principales: | Marcella, Stephen, Kobic, Emir, Carr, Amy L, Georgiades, Benjamin, Margiotta, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752166/ http://dx.doi.org/10.1093/ofid/ofac492.718 |
Ejemplares similares
-
Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration
por: Kobic, Emir, et al.
Publicado: (2022) -
Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
por: Stracquadanio, Stefano, et al.
Publicado: (2022) -
Acinetobacter baumannii response to cefiderocol challenge in human urine
por: Nishimura, Brent, et al.
Publicado: (2022) -
Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii
por: Raro, Otávio Hallal Ferreira, et al.
Publicado: (2023) -
Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
por: Kobic, Emir, et al.
Publicado: (2021)